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Update to the FOCUS, AFFINITY and EFFE
CTS trials studying the effect(s) of
fluoxetine in patients with a recent stroke:
statistical analysis plan for the trials and for
the individual patient data meta-analysis
Gillian Elizabeth Mead1*, Catriona Graham2, Laurent Billot 3, Per Näsman4, Erik Lundström5, Steff Lewis6,
Graeme J. Hankey7, Maree L. Hackett3 , John Forbes8, Martin Dennis9 and On behalf of the FOCUS, AFFINITY and
EFFECTS trialists
Abstract
Background: Three large trials of fluoxetine for stroke recovery (FOCUS (fluoxetine or control under supervision),
AFFINITY (the Assessment oF FluoxetINe In sTroke recovery) and EFFECTS (Efficacy oF Fluoxetine—a randomisEd
Controlled Trial in Stroke)) have been collaboratively designed with the same basic protocol to facilitate an
individual patient data analysis (IPDM). The statistical analysis plan for the three individual trials has already been
reported in Trials, including a brief description of the IPDM. In this protocol, we describe in detail how we will
perform the IPDM.
Methods/design: Data from EFFECTS and AFFINITY will be transferred securely to the FOCUS statistician, who will
perform a one-stage IPDM and a two-stage IPDM. For the one-stage IPDM, data will be combined into a single data
set and the same analyses performed as described for the individual trials. For the two-stage IPDM, the results for
the three individual trials will be combined using fixed effects meta-analyses.
The primary and secondary outcome domains for the IPDM are the same as for individual trials. We will also
perform analyses according to several subgroups including country of recruitment, ethnicity and trial. We will also
explore the effects of fluoxetine on our primary and secondary outcomes in subgroups defined by combinations of
characteristics.
We also describe additional research questions that will be addressed using the combined data set, and published
subsequently, including predictors of important post-stroke problems such as seizures, low mood and bone fractures.
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Discussion: An IPDM of our three large trials of fluoxetine for stroke recovery will allow us to provide the most precise
estimates of any risks and benefits of fluoxetine vs placebo, to detect reliably a smaller overall effect size than those
detectable by the individual trials, to better determine the effects of fluoxetine vs placebo in subgroups of patients and
outcomes and to broaden the generalisability of the results. Also, we may identify differences in treatment effects
between studies.
Trial registration: FOCUS: ISRCTN ISRCTN83290762. Registered on 23 May 2012. EudraCT 2011-005616-29. Registered
on 3 February 2012.
AFFINITY: Australian New Zealand Clinical Trials Registry ACTRN12611000774921. Registered on 22 July 2011.
EFFECTS: ISRCTN ISRCTN13020412. Registered on 19 December 2014. ClinicalTrials.gov NCT02683213. Registered on 2
February 2016. EudraCT 2011-006130-16. Registered on 8 August 2014.
Keywords: Stroke, Recovery, Individual patient data meta-analysis, FOCUS, AFFINITY, EFFECTS
Background
Burden of stroke
Despite recent advances in hyperacute treatments and
secondary prevention, stroke is still a major cause of
death and severe disability in the community [1, 2]. In
low- and middle-income countries, the burden of stroke
is increasing. Thus, further research is needed to identify
new treatments that will reduce the burden of stroke
disease globally.
Fluoxetine and stroke recovery
In 2011, the FLAME trial (fluoxetine in motor recov-
ery of patients with acute ischaemic stroke) reported
that a 3-month course of fluoxetine given within 5 to
10 days of onset of ischaemic stroke improved motor
recovery and increased functional independence com-
pared to placebo [3]. This led to the development of
three larger trials of fluoxetine for stroke recovery,
which aimed to determine whether fluoxetine given
early after stroke (2 to 15 days post-onset, either is-
chaemic or haemorrhagic stroke) increased functional
independence at 6 months [4]. These trials (FOCUS
[Fluoxetine or Control Under Supervision], AFFINITY
[Assessment oF FluoxetINe In sTroke recoverY] and
EFFECTS [Efficacy oF Fluoxetine—a randomisEd Con-
trolled Trial in Stroke]) were collaboratively designed,
had the same basic protocol, but with the option of
adding additional outcomes. FOCUS published its re-
sults among 3127 patients in December 2018: there
was no effect of fluoxetine on the primary outcome
of modified Rankin scale (mRS), but those allocated
to fluoxetine were less likely to develop depression by
6 months and were more likely to have had a bone
fracture [5]. AFFINITY (n = 1280 [6]) and EFFECTS
(n = 1500 [7]) published their 6-month data in August
2020. The findings were nearly identical to those in
FOCUS: there was no effect of fluoxetine on the
mRS, but those allocated to fluoxetine were less likely
to develop depression in the EFFECTS trial and were
more likely to have had a bone fracture in the AFFI
NITY and EFFECTS trials.
Pre-planned individual patient data meta-analysis of
FOCUS, AFFINITY and EFFECTS
When the collaboration was initiated, we published
a core protocol for the trials and agreed to perform
an individual patient data meta-analysis (IPDM)
after all three trials had reported their primary re-
sults [4].
We considered whether to include other trials of
fluoxetine in our IPDM. However, we know from
our first Cochrane review and meta-analysis of ran-
domised controlled trials of selective serotonin re-
uptake inhibitors for stroke recovery [8] that low-
quality trials tend to give positive results whilst
high-quality trials do not. Although there were two
other trials of fluoxetine which were at low risk of
bias [3, 9] (recruiting 118 and 32 patients respect-
ively), they were substantially different in their de-
sign from FOCUS, AFFINITY and EFFECTS (e.g.
different inclusion criteria, shorter duration of treat-
ment and different outcome measures). Thus, we de-
cided to limit our IPDM to FOCUS, AFFINITY and
EFFECTS. We have, however, included these other
two high-quality trials [3, 9] in a systematic review
and traditional meta-analysis of fluoxetine for stroke
recovery [10] and in the updated Cochrane system-
atic review (2019) [11]. When the Cochrane review
is updated again, we will include other new trials of
fluoxetine for stroke recovery.
There are multiple advantages of IPDM over trad-
itional meta-analysis which combines aggregate effect
sizes from each trial [12]. Meta-analysis results for spe-
cific subgroups of participants can be obtained across
studies and differential (treatment) effects can be
assessed across individuals, which can help reduce
between-study heterogeneity. An IPDM of our three tri-
als will allow us to provide the most precise estimates of
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any risks and benefits, to detect reliably a smaller overall
effect size than those detectable by the individual trials,
to better determine the effects of fluoxetine vs pla-
cebo in subgroups and to broaden the generalisability
of the results. Also, an IPDM can identify if, and
where, the treatment effect of fluoxetine and placebo
differs between studies since we hypothesise that the
treatment effect might be influenced by characteristics
of the local healthcare systems and the local trial
processes.
The main drawback of an IPDM is the resources and
time needed to obtain the data from the trialists and to
perform the analyses. However, our data have been col-
lected in a way to facilitate sharing, and the statistical
analyses of the individual trials are performed using the
same pre-specified analyses.
We have already published a brief description of
the IPDM as part of our statistical analysis plan for
the three trials [13]. We now describe in detail the
methods for our IPDM, following the standard re-
quirements for the rationale, conduct and reporting
of an IPDM [12].
Aim
We will perform an IPDM of FOCUS, AFFINITY and
EFFECTS data. Initially, we will include only the 6-
month follow-up data (which includes our primary out-
come measure). We will report the 12-month data in a
subsequent publication. This decision was made before
knowing the results of AFFINITY and EFFECTS. We
will therefore be able to expedite the IPDM and thus
provide important analyses that will inform clinical prac-
tice and help researchers make decisions about whether
further trials of SSRI for stroke are needed. The objec-
tives below describe the analyses at 6 months and 12
months.
Objectives
Primary objective
We will determine whether patients with a clinical
stroke diagnosis (2 to 15 days after onset) who are pre-
scribed a 6-month course of fluoxetine 20mg daily have
improved functional outcome, as defined by the modi-
fied Rankin Scale (mRS) score at 6 and 12 months, com-
pared with placebo [4].
Pre-specified secondary objectives (aligning with sec-
ondary analyses for the individual trials) [4, 13]:
1 Does fluoxetine influence the secondary outcomes
(fatigue, individual stroke impact score domains,
cognition, mood, quality of life and living
circumstances) at 6 months and 12 months? In
addition to the analysis of individual stroke impact
score (SIS) domains, we will derive a motor score
and a physical function score from relevant
individual items [4].
2 If fluoxetine improves mRS score at 6 months, does
any improvement persist after treatment stops?
3 Does fluoxetine increase the risk of serious adverse
events?
4 Is fluoxetine associated with longer-term survival?
The survival analysis will be by the Kaplan-Meier
technique and the groups compared by the Cox
proportional hazards analysis, expressed as a hazard
ratio.
5 Is the effect of fluoxetine vs placebo on the
primary outcome modified by any of the
following: stroke pathology, age, stroke severity
(based on the six variable model and the
National Institutes of Health stroke scale (NIHS
S)), patients unable to consent for themselves,
inability to assess mood because of
communication or cognitive problems, and
patients with and without depression at
baseline?
6 In patients with motor deficits at randomisation,
does fluoxetine improve motor function as
measured by the SIS motor, and is the effect of
fluoxetine modified by the severity of the stroke, as
measured by the NIHSS?
7 In patients with aphasia at randomisation, does
fluoxetine reduce aphasia?
8 Is there a relationship between functional status at
6 months and mood, and is this relationship
affected by fluoxetine?
9 How does non-adherence to the study protocol in-
fluence outcome?
Additional pre-specified secondary analyses in the
IPDM:
10 Does the effect of fluoxetine vs placebo vary by
country of randomisation (UK, Australia, Vietnam,
New Zealand, Sweden)? Note that this is not the
same as by trial. If we do not have sufficient
numbers of patients from one of the countries to
ensure that anonymity is preserved, we will perform
this analysis by trial only.
11 Does the effect of fluoxetine vary by ethnicity? This
will overlap to some extent with country.
12 Does the effect of fluoxetine vary by trial? This will
also overlap with country and ethnicity.
Data-driven exploratory analyses
Data-driven analyses will be conducted to address
heterogeneous treatment effects. The aim is to look
at subgroups of patients who may respond differ-
ently from others to fluoxetine, e.g. at higher risk of
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adverse effects, of gaining more benefit etc. This
was considered for FOCUS, but there were insuffi-
cient data to perform these analyses. Subpopulations
with different average treatment effects will be iden-
tified using ‘regression tree’ or ‘recursive partition-
ing’ methods [14]. These data-driven analyses will
be identified as such when we report the IPDM
results.
Resource use and cost-effectiveness: future analyses
Each trial is collecting data about resource use over
the first 12 months of follow-up to enable us to carry
out health economic analyses [4, 13]; these will be
trial-specific, but a combined analysis will be under-
taken including data common to all three trials. It
will be led by the health economists in our collabora-
tive group and will be reported in a subsequent publi-
cation. The statistical analysis plan for the individual
trials describes the health economic analyses in more
detail [13]. A separate protocol will be developed for
these analyses.
Patient eligibility criteria for inclusion in the
IPDM
We will include all the patients who were randomised in
the three trials. We will exclude those who consented
but were not subsequently randomised.
In FOCUS, there was a small number of patients
where the 6-month outcome data were obtained too
early (less than 90 days) or too late (more than 1 year
from randomisation); in the IPDM, these will be dealt
with in the same way as in FOCUS, i.e. if the mRS score
was available between 90 days and 1 year, we included it
within our primary analysis based on the 6-month
follow-up. If it was not between these times, it was not
used. If after 1 year, it would have been used for 12-
month analyses.
We will do a sensitivity analysis sequentially ex-
cluding patients, starting with those who did not
meet the entry criteria for the trials. This has already
been described in detail in the statistical analysis
plan for the individual trials [13]. We will do these
sequential exclusions in the same way as we did in
FOCUS, which means that those without stroke will
be excluded. Note that in FOCUS the numbers were
very small.
Studies to be included in the IPDM
We pre-specified that we would include FOCUS,
AFFINITY and EFFECTS in this IPDM. Thus, we are
not reporting in this protocol the study selection
processes.
Data collection process
The FOCUS statisticians will merge the data sets
from the three trials to produce a combined data set
that is ‘future proofed’, to enable new research ques-
tions identified in the future to be addressed. The
combined data set will include all variables, even if
only collected by one or two of the trials.
Data items
In the IPDM, we will include the core data items (base-
line and outcome data) which have been collected in all
three trials and any measures that are common to at
least two of the individual trials.
The following outcome domains are common to
all three trials, but different variables have been
collected:
a) Cognition. The SIS which incorporates an
assessment of memory and thinking that was
collected for all three trials. An IPDM will be
performed for those data. In AFFINITY,
cognition during follow-up is assessed with the
Modified Telephone Interview for Cognitive
Status (TICSm). EFFECTS assessed cognition
with the Montreal Cognitive Assessment
(MoCA) at baseline, 3 months and 6 months
(face-to-face); these scales will not be merged.
When we update the Cochrane review of SSRI
for stroke recovery, we will use standardised
mean difference (SMD) to combine data from
different scales.
b) Mood. All three trials report ‘a new diagnosis
and/or treatment of depression during follow-up’.
FOCUS and EFFECTS also report the Mental
Health Inventory 5. These will be combined in
the IPDM. There are also data from the PHQ-9
in AFFINITY and MADRS in EFFECTS; these
scales will not be combined in this IPDM. When
we update the Cochrane review of SSRI for
stroke recovery, we will use SMD to combine
these scales.
Data dictionary
We have developed a data dictionary based on
FOCUS records, which has ~ 500 variables coded.
This will be sent to the AFFINITY and EFFECTS tri-
alists. The FOCUS data dictionary will enable EFFE
CTS and AFFINITY trialists to align their data dic-
tionaries to FOCUS, so that the same variables are
coded in the same way for each trial. Thus, when
AFFINITY and EFFECTS data are made available to
FOCUS statisticians, minimal manipulation will be re-
quired to merge the data sets.
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Transfer of data from AFFINITY and EFFECTS to the
FOCUS statistician
After the data dictionaries have been aligned, AFFI
NITY and EFFECTS trialists will transfer their anon-
ymised data to the FOCUS statisticians. Initially, this
will include all data collected up to 6 months. When
the 12-month data become available, these will also
be provided. The process of data transfer will be de-
termined by the governance processes in each coun-
try; this is likely to be using file exchange via secure
FTP (SFTP).
Merging the trial data sets
FOCUS own the FOCUS data. AFFINITY and EFFECTS
own their respective data but have given permission for
these data to be combined with FOCUS.
The merged data sets will be stored in the University
of Edinburgh Data store, along with a detailed data
dictionary and descriptors and a description of how
the merging was done. FOCUS data will be shared as
part of the researchers’ responsibilities to the funder.
Further discussion is needed about whether, and if so,
how, to share the merged data set with other re-
searchers; we will follow the recommendations of the
three funders and the institutions which hosted the
three trials.
Whilst the statistician performing the IPDM works
on the combined data set, it will be password pro-
tected and the analysis will be done in a locked office.
SAS will be used for the statistical analysis. Note that
the health economic IPDM may be performed using
different programmes.
Tables of results for IPDM
We will report baseline data for the three trials individu-
ally and together, the outcome measures for the individ-
ual trials and the combined data set, and the subgroups
of interest for the individual trials and the combined data
set (Table 1 in the Appendix, Table 2 in the Appendix
and Table 3 in the Appendix). These align with our re-
search questions.
Risk of bias assessment in individual studies
The risk of bias for each trial will be assessed by
two independent people outside of the author team
using the Cochrane risk of bias tool 2 [15]. These
two people will be identified after the publication
of this protocol. They will be independent of the
trialists and will have had previous experience of
using either the first or second Cochrane risk of
bias tool.
Specification of outcomes and effect measures
The outcomes listed in the statistical analysis plan for
the three trials [13] are the mRS score, the SIS, the
vitality component of SF-36 (for fatigue), mood,
EQ5D-5L (quality of life), adverse events and living
circumstances.
Synthesis methods
Descriptive analyses of the three trials (Table 1 in the
Appendix)
Descriptive and exploratory analyses will be under-
taken initially to identify and display differences in
baseline characteristics between the types of patients
enrolled in the three trials, specifically statistical com-
parisons of baseline means and medians. We will use
ANOVA to explore whether there is evidence of a
difference across trials. Also, we will describe the dur-
ation and type of hospital stays between randomisa-
tion and discharge home, discharge to a residential or
nursing home, or death.
Each trial will be re-analysed individually to ensure
that the main results can be reproduced. If that is
not the case, the differences must be resolved before
proceeding with the IPDM meta-analysis.
IPDM
We have considered whether to do a one- or two-
stage IPDM [16]. There are advantages and disadvan-
tages to both approaches. A one-stage model com-
bines all patient data from all studies in one single
model and takes advantage of the combined data set.
It also gives greater flexibility and power than the al-
ternative two-stage method but can be more complex
and difficult to interpret. The two-stage method in-
volves the creation of summary statistics then com-
bining the summary statistics using standard meta-
analysis methods, but the drawback of this approach
is that it can be biased.
We have decided to do both approaches as a sen-
sitivity analysis. The one-stage approach will pro-
vide estimates of effect, and the two-stage approach
will provide Forest plots. Generally, the two ap-
proaches should give the same answer [16], but if
the approaches give different answers, we will ex-
plore the reasons for this. In general, different an-
swers from the two methods tend to be obtained
when included studies are small and/or when an ef-
fect is large, or events are rare [16]. This is unlikely
to be the case for this IPDM as the three studies
are large. Furthermore, the effects in FOCUS were
small, and results from EFFECTS and AFFINITY
are awaited.
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One-stage approach
We will perform the same analyses that have been de-
scribed for the individual trials on the combined data
set. This has been described in the FOCUS trial publica-
tion [5]. This will be a regression model, with a separate
term for each trial.
Two-stage approach
Ordinal logistic, logistic and Cox proportional haz-
ards regressions will be performed separately for
each trial, as described for the main within-trial ana-
lysis. Then, the point estimate and standard error of
the treatment effect from the within-trial analyses
will be meta-analysed using a generic inverse vari-
ance model. Fixed effect analyses will be performed
and presented as there are only three studies and so
the estimate of the between-study variability will be
poor. Forest plots will be produced to display
results.
How missing data within the IPDM will be dealt
with
Our randomisation systems did not allow investigators
to proceed to treatment allocation without entering
complete baseline data. The mRS, our primary out-
come, includes death, so it is expected that the num-
ber with missing mRS data at follow-up will be
minimal. The primary analysis will be a complete case
analysis (i.e. anyone with missing mRS data will not
be included in any analysis requiring mRS). Multiple
imputations will only be performed if the proportion
of data missing is > 5%.
For secondary outcomes where missing data are ex-
pected because data will not be available for patients
who did not survive, we will present results for those
who are alive at follow-up; any discrepancy in death
rates between groups will be considered in the interpret-
ation. Missing data for single questions within scores
will be handled as described by each scoring method.
Immediately before database lock for each trial, a
blinded review of the completeness of primary and sec-
ondary outcomes is performed. For items such as SF36,
if there are at least 50% of questions within a domain
that have responses, we are able to use the methods de-
tailed by the standardised tools to calculate a value for
the domain.
If higher levels of missing mRS data than expected
(> 5%) are seen, we will consider additional sensitiv-
ity analyses to assess the robustness of the results
against various assumptions about the missing data
mechanism as outlined in Jakobsen et al. [17]. Given
the exact nature of these additional sensitivity ana-
lyses is not pre-specified, they will be considered
exploratory.
Primary analysis
This addresses the primary research question: does the
routine administration of fluoxetine 20mg daily for
6 months after an acute stroke improve patients’ func-
tional recovery at 6 months?
Secondary analyses
Secondary outcomes
We will report the secondary outcomes at 6 and 12
months for the combined data set, as we have done for
the individual trials and as described in the statistical
analysis plan for the individual trials.
Subgroup analyses
We will perform subgroup analyses as we have done for
the individual trials. The mRS data at 6 months will be
compared using an ordinal logistic regression using our
adjusted model, and comparison will be made across
variables listed in Table 1 in the Appendix. Each sub-
group will be considered separately by adding the sub-
group variable and its interaction with the treatment
variable to the main model. This includes examining
individual and group covariates of substantive interest
such as stroke severity (NIHSS) and the six simple
variable model for prognosis [4]. Potential covariates
and other baseline data are shown in Table 1 in the
Appendix. Additionally, we will explore the impact of
trial (FOCUS, AFFINITY, EFFECTS), country and
ethnicity. This will enable us to explore variation in
effects.
Sensitivity analyses
We will sequentially exclude patients from the trials to
explore the influence of non-eligible patients being re-
cruited, and compliance with the trial medication as
already described in detail in the statistical analysis plan
for the individual trials [13].
Data-driven (additional) analyses
Data-driven analyses will be conducted to address
heterogeneous treatment effects. Subpopulations
with different average treatment effects will be iden-
tified using ‘regression tree’ or ‘recursive partition-
ing’ methods [14]. These data-driven analyses will
complement the pre-specified subgroup analyses.
Risk of bias across studies
We will rate the certainty of the evidence of the
IPDM using Cochrane Grades of Recommendation,
Assessment, development, and Evaluation (GRADE)
[18].
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Reporting of results
We will produce a PRISMA IPDM diagram; this will
not include results of searches for studies as we have
pre-specified that we are using only data from three
trials. We will list available data and analysed data
(i.e. the final two steps in a standard PRISMA IPDM
diagram) [19].
We will report results in individual trials and re-
sults in the combined data set (the one-stage ap-
proach) as shown in results Table 1 in the
Appendix, Table 2 in the Appendix and Table 3 in
the Appendix for baseline, subgroup and pre-
specified outcomes.
We will produce Forest plots for the two-stage ap-
proach (i.e. where trials are analysed independently
and then meta-analysed) for all the pre-specified out-
comes. However, there are likely to be too many plots
to present in a publication. As a minimum, we will
include the plot for the primary outcome, which will
include effects in the individual pre-specified sub-
groups. We will describe the other outcomes in the
text as well as making them available on reasonable
request, or in an appendix, depending on the journal
requirements.
The text will report study characteristics, IPDM
integrity, risk of bias within studies, results of indi-
vidual studies (including the impact of compliance
on the results), results of syntheses, risk of bias
across studies and any additional analyses
performed.
Discussion of IPDM
In the discussion, we will summarise evidence, its
strengths and limitations, how it fits with existing litera-
ture, our conclusions and the implications for clinical
practice, future research and policy.
Further possible analyses of the combined data
set
There are several other research questions that can
be addressed using the combined data set. Each of
these questions will require a separate statistical
analysis plan to be developed. These questions
include:
a) What are the types of bone fractures after stroke?
What is their impact on mRS? What factors are
associated with fracture risk? We have already
published these data from FOCUS and can repeat
the same analyses on the combined data set. Note
that falls will be included in the interpretation of
these results.
b) What are the baseline predictors of seizure risk
after stroke? What drugs are associated with
increased seizure risk? How does fluoxetine modify
this effect?
c) What are the baseline predictors of depression after
stroke? How is depression at 6 months associated
with disability and dependency?
d) What factors are associated with pain after
stroke (using pain item from EQ5D-5L)? This
includes baseline predictors and factors that
might influence pain severity, e.g. mood
disorders.
e) What are the baseline predictors of fatigue after
stroke? Fatigue is measured using the SF-36 vitality
component. How does fatigue relate to mood and
does it predict case fatality?
f) How does the short version of the Stroke Impact
Scale (using a single item from each domain)
relate to the full Stroke Impact Scale? This is an
important question for researchers who are
considering using the Short Stroke Impact Scale
in future research.
g) What is the effect of fluoxetine on 90-day
home-time, and what is the relationship between
home-time and mRS across countries? Home-
time is a measure of the time spent back at the
person’s home during a predefined period after
a stroke [20].
Trial status
FOCUS recruited its first patient on 10 September 2012
and its last on 31 March 2017 and published its results
in December 2019.
AFFINITY recruited its first patient on 11 January
2013 and its last patient on 30 June 2019.
EFFECTS recruited its first patient on 20 October
2014 and its last patient on 28 June 2019.
Appendix
As stated in the initial statistical analysis plan, we will
show data from all three trials as well as data from
the merged data set. However, the table will be large
and so data from the individual trials may need to be
included in an appendix, and only data from the
merged data set included in the main part of the
paper.
The following table is based on the assumption that all
the data are present; where this is not the case, denomi-
nators will be indicated to provide the reader with a
clear idea of the numbers that each percentage was cal-
culated from.
Note: this table is different from the data dictionary.
The data dictionary is a separate document that is about
40 pages long and lists ~ 500 variables.
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